Associate Professor, Medicine, University of Florida College of Medicine
Cardiology
Dr. Dominick J. Angiolillo, MD
|
|
Give Review
Dominick J. Angiolillo is an expert in the field of Cardiology. He received 1 awards: "Fellow (FACC)". Dominick Angiolillo is also a published MD. He has 104 paper published. The most recent paper is: Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. Dominick Angiolillo accepts all Medicare patients.
Publications
- Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in Acute coronary syndrome patients.
- Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
- Effects of dabigatran on the cellular and protein phase of coagulation in patients with Coronary artery disease on dual antiplatelet therapy with aspirin and clopidogr...
- Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
- Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
- A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
- A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with Coronary artery disease: results of a prospecti...
- Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous Coronary intervention and discharged on dual an...
- Switching P2Y12-receptor inhibitors in patients with Coronary artery disease.
- Novel Antiplatelet Agents: the Current State and What is Coming Down the Pike.
- Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothromb...
- Pretreatment with antiplatelet drugs in invasively managed patients with Coronary artery disease in the contemporary era: review of the evidence and practice guidelines.
- Acute coronary syndromes: applying practice guidelines and defining the unmet need in clinical practice.
- Perioperative management of oral antiplatelet therapy and clinical outcomes in Coronary stent patients undergoing surgery. Results of a multicentre registry.
- A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable Coronary artery disease.
- Novel antiplatelet agents in Acute coronary syndrome.
- Impact of GEne Polymorphisms, Platelet REactivity and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Un...
- Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease.
- Aspirin treatment and outcomes in patients undergoing percutaneous Coronary intervention: is there a role for pharmacodynamic testing?
- Perspectives on the management of antiplatelet therapy in patients with Coronary artery disease requiring cardiac and noncardiac surgery.
- Percutaneous Coronary intervention and atrial fibrillation: the triple therapy dilemma.
- The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronar...
- Operator Radiation Exposure and Physical Discomfort During a Right Versus Left Radial Approach for Coronary Interventions: A Randomized Evaluation.
- Platelet function testing in contemporary clinical and interventional practice.
- Transferring from clopidogrel loading dose to prasugrel loading dose in Acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET...
- Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Prasugrel-Treated Patients.
- Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of Acute coronary syndromes or percutaneous coronary intervent...
- Cigarette Smoking and Antiplatelet Effects of Aspirin Monotherapy Versus Clopidogrel Monotherapy in Patients with Atherosclerotic Disease: Results of a Prospective Pha...
- Detecting Thienopyridine Effect By Platelet Reactivity Assessment and Its Implications for Risk Stratification.
- Management of antiplatelet therapy in patients with Coronary artery disease requiring cardiac and noncardiac surgery.
- Impact of Mild Hypothermia on Platelet Responsiveness to Aspirin and Clopidogrel: an In Vitro Pharmacodynamic Investigation.
- Percutaneous Coronary Interventions in ST-Segment-Elevation Myocardial Infarction: Shifting Paradigms and Future Perspectives.
- Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring Chronic nons...
- Impact of Cigarette Smoking on P2Y12 Receptor Binding Activity Before and After Clopidogrel Therapy in Patients with Coronary Artery Disease.
- Impact of Smoking on Long-Term Outcomes in Patients with Atherosclerotic Vascular Disease Treated with Aspirin or Clopidogrel: Insights from the Clopidogrel versus Asp...
- Cangrelor: a review on pharmacology and clinical trial development.
- Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and Coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vi...
- Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial.
- Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with Coronary artery disease.
- Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and Bleeding.
- Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone: Transferring From Clopidogre...
- Enhanced active metabolite generation and platelet inhibitionwith prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
- Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.
- Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and Coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot in...
- Impact of aspirin dose on adenosine diphosphate-mediated platelet activity. Results of an in vitro pilot investigation.
- Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents.
- Clopidogrel pretreatment in primary percutaneous Coronary intervention: Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the ...
- The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study.
- Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring Coronary artery bypass surgery.
- Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events.
- Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
- Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
- Platelet Function Profiles in Patients with Diabetes Mellitus.
- Switching from prasugrel to clopidogrel: navigating in unknown waters.
- Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.
- Switching antiplatelet regimens: Alternatives to clopidogrel in patients with Acute coronary syndrome undergoing PCI: A review of the literature and practical consider...
- Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study.
- Pharmacodynamic effects of adjunctive cilostazol therapy in patients with Coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet re...
- Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study.
- Effects of cangrelor in Coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.
- The evolution of antiplatelet therapy in the treatment of Acute coronary syndromes: from aspirin to the present day.
- Impact of renal function on clopidogrel-induced antiplatelet effects in Coronary artery disease patients without diabetes mellitus.
- Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice.
- Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.
- Advances in platelet function testing assessing bleeding complications in patients with Coronary artery disease.
- Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.
- Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platel...
- Atopaxar: a review of its mechanism of action and role in patients with Coronary artery disease.
- Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Diseases.
- Pharmacokinetic and Pharmacodynamic Effects of Elinogrel: Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evalua...
- Targeting Platelet Nitric Oxide Resistance With Ramipril: Unraveling Mechanisms of Atherothrombotic Risk Reduction With Angiotensin-Converting Enzyme Inhibitors.
- Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and Coronary artery disease: results of a pharmacody...
- Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes with Clopidogrel and Ticagrelor: Insights from PLATO.
- Unravelling the benefit against the risk of long-term dual antiplatelet therapy.
- Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular Disease.
- Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
- Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase...
- Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums.
- Antithrombotic therapy in patients with atrial fibrillation undergoing Coronary stenting: a north american perspective: executive summary.
- Applying platelet function testing in clinical practice: what are the unmet needs?
- Impact of gastric Acid-suppressing therapies on platelet reactivity in patients with Coronary artery disease treated with clopidogrel results of a pharmacodynamic study.
- Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y1...
- Current concepts on Coronary revascularization in diabetic patients.
- Response to letter regarding article, "pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with Coronary artery disease".
- Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and Coronary artery disease on dual antiplatelet therapy with aspirin ...
- Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus.
- Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and Coronary artery disease.
- Unraveling myths of platelet function and genetic testing the road to making tailored antiplatelet therapy a reality.
- Assessment of Dynamic Coronary Plaque Changes and the Clinical Consequences in Type-II Diabetic Patients: a Serial IntraCoronary Ultrasound Study.
- Can resistance to aspirin be reversed after an additional dose?
- Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects: Results of a Prospective, Randomized, Crossover Study.
- Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with Coronary artery disease.
- Optimizing platelet inhibition in clopidogrel poor metabolizers therapeutic options and practical considerations.
- Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease.
- Clopidogrel-drug interactions.
- Diabetes and antiplatelet therapy in Acute coronary syndrome.
- Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation.
- Antithrombotic therapy in the elderly.
- Investigations on 5-HTâ‚„ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
- Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
- Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
- Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
- Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Dissection
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- AvMed
- Blue Card PPO
- Blue Care HMO
- Blue Select
- BlueDental Choice
- NetworkBlue
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health Care
- Employer Group PPO
- First Health (Coventry Health Care) PPO
- GEHA
- Choice Care PPO
- Preferred PPO
- Select HMO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Fellow (FACC)
Education
-
University of Florida -
University of Cattolica del Sacro Cuore
Hospital
-
UF Health Jacksonville
Drug Facts
| NPI NUMBER | 1578687844 | |
| NPPES Provider LastName | ANGIOLILLO | |
| NPPES Provider FirstName | DOMINICK | |
| NPPES Provider ZIPCode | 322096511 | |
| NPPES Provider State | FL | |
| Specialty Description | Cardiology | |
| Total Claim Count | 296.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578687844 |
| Last Name Of The Provider | ANGIOLILLO |
| First Name Of The Provider | DOMINICK |
| View All |
Similar Doctors
|
|
Dr. Alan B. Miller, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Gary J. Snyder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory C. Tomlinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph L. Blackshear, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold P. Dietzius, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Abdul R. Kani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan Constantin, MD |
|
|
Dr. Steven S. Nauman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gabriel B. Mufuka, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arne S. Sippens Groenewegen, MD
This Doctor is OpenDoctor Recommended.
|